Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD70 CAR-T cells · 3 trials · 8 indications
Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
Dose-limiting toxicity after cell infusion
| Arm | Type | Description |
|---|---|---|
| Intravenous of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CD70-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg |
| intraperitoneal injection of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CD70-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg |
| Name | Type | Description |
|---|---|---|
| CD70 CAR-T cells | BIOLOGICAL | After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically |
Inclusion Criteria: 1. Age ≥18 years old; 2. Advanced/metastatic gynecological tumor confirmed by histopathology or cytology (paraffin sections or fresh biopsy tumor tissue specimens) (CD70 positive tumor expression (CD70 positive tumor confirmed by histology or pathology (IHC 3+)); 3. Failure or i...
Top 20 of 45 competitors
CD70 CAR-T cells is an investigational cell therapy being studied for the treatment of CD70-positive advanced or metastatic solid tumors, including ovarian cancer, renal cell carcinoma, and cervical cancer. It is currently in Phase 1 clinical trials enrolling adult patients in China.
CD70 CAR-T cells targets the CD70 antigen, which is expressed on certain tumor cells. The therapy is designed to recognize and attack CD70-positive cancer cells in patients with advanced or metastatic solid tumors.
CD70 CAR-T cells is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol DTIL. The company is conducting Phase 1 clinical trials for this investigational cell therapy.
CD70 CAR-T cells is in Phase 1 clinical development. It is an investigational therapy and has not yet been approved by regulatory authorities. The ongoing trials are recruiting patients to evaluate its safety and efficacy.
CD70 CAR-T cells is being studied in three Phase 1 clinical trials: NCT05518253, NCT06010875, and NCT06215950. These trials are recruiting patients with CD70-positive advanced or metastatic solid tumors, including ovarian, renal cell, and cervical cancers, at sites in China.
CD70 CAR-T cells is a specific CAR-T cell therapy targeting the CD70 antigen. While it shares the general CAR-T approach with other therapies, it is distinct in its target and is being developed by Precision BioSciences for solid tumor indications.